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THROMBOSIS AND HEMOSTASIS
The interplay between tissue plasminogen activator domains and fibrin structures
in the regulation of fibrinolysis: kinetic and microscopic studies
Colin Longstaff,1 Craig Thelwell,1 Stella C. Williams,1 Marta M. C. G. Silva,1 La´szlo´ Szabo´,2 and Krasimir Kolev3
1Biotherapeutics Group, Haemostasis Section, National Institute for Biological Standards and Control, South Mimms, United Kingdom; 2Chemical Research
Center, Hungarian Academy of Sciences, Budapest, Hungary; and 3Department of Medical Biochemistry, Semmelweis University, Budapest, Hungary
Regulation of tissue-type plasminogen
activator (tPA) depends on fibrin bind-
ing and fibrin structure. tPA structure/
function relationships were investigated
in fibrin formed by high or low thrombin
concentrations to produce a fine mesh
and small pores, or thick fibers and
coarse structure, respectively. Kinetics
studies were performed to investigate
plasminogen activation and fibrinolysis
in the 2 types of fibrin, using wild-type
tPA (F-G-K1-K2-P, F and K2 binding),
K1K1-tPA (F-G-K1-K1-P, F binding), and
delF-tPA (G-K1-K2-P, K2 binding). There
was a trend of enzyme potency of tPA >
K1K1-tPA > delF-tPA, highlighting the
importance of the finger domain in regu-
lating activity, but the differences were
less apparent in fine fibrin. Fine fibrin
was a better surface for plasminogen
activation but more resistant to lysis.
Scanning electron and confocal micros-
copy using orange fluorescent fibrin
with green fluorescent protein-labeled
tPA variants showed that tPA was
strongly associated with agglomerates
in coarse but not in fine fibrin. In later
lytic stages, delF-tPA-green fluorescent
protein diffused more rapidly through
fibrin in contrast to full-length tPA, high-
lighting the importance of finger domain-
agglomerate interactions. Thus, the
regulation of fibrinolysis depends on
the starting nature of fibrin fibers and
complex dynamic interaction between
tPA and fibrin structures that vary over
time. (Blood. 2011;117(2):661-668)
Introduction
Fibrin may be viewed as a substrate according to 2 distinct
definitions of the word: (1) a surface or layer supporting biologic
activity and (2) a substance acted on by an enzyme. The mechanism
of tissue-type plasminogen activator (tPA) stimulation by fibrin is
by “colocalization” of tPA and plasminogen on fibrin, which acts as
a substrate (definition 1) or template; and the plasmin generated in
this way is the enzyme that digests fibrin substrate (definition 2).
Fibrinolysis encompasses both processes, which are distinct but
overlapping. The role of fibrin structure in regulating the whole
process of fibrinolysis is not completely understood, and there is
disagreement over published results. For example, fibrin fiber
diameter can be manipulated by thrombin, such that higher
thrombin concentrations produce a fine network of thin fibers,
whereas fibrin polymerization at lower thrombin concentration
results in more lateral aggregation and produces clots composed of
thicker fibers, as reviewed.1 It has been observed from gross
changes in turbidity of fibrin clots undergoing lysis2,3 that clots
made of thicker fibers appear to lyse more rapidly than clots made
from fine fibers. However, this simple relationship has been
questioned because clots made of thicker fibers are more turbid and
lysis may appear to be faster when followed optically if turbidity is
not normalized to correct for different starting values.1 Further-
more, it has been noted from more detailed microscopic studies that
thinner fibers are more susceptible to lysis than thick fibers, yet this
relationship is not reflected in the behavior of whole clots.4,5 The
relationship between clot turbidity and lysis is further complicated
by frequently observed transient increases in turbidity during lysis6
and by some observations that some peptides corresponding to
portions of fibrin(ogen) can increase turbidity and confer resistance
to lysis.7 Thrombi formed from whole blood, as opposed to purified
fibrinogen and thrombin, are clearly more complex and heteroge-
neous environments for fibrinolysis (or thrombolysis) to occur, but
the nature of the fibrin present is generally observed to resemble the
coarse fiber fibrin organization seen in purified systems formed at
lower thrombin concentrations.8 Hypofibrinolysis is a risk factor
for cardiovascular disease and can arise in a number of situations
because of abnormal clot structure, for example, where there are
high fibrinogen concentrations9,10 or because of variants of fibrino-
gen that form high density fibrin clots.11,12 However, additional
constituents, such as platelets, cause local disturbances where fibrin
structure becomes denser, more closely resembling the fine fibrin
structures seen in clots made at high thrombin concentrations.13
Fibrinolysis is dependent on plasminogen and tPA binding via
specific domain interactions. There are 5 distinct structural do-
mains in tPA, comprising Finger-Growth factor-Kringle 1-Kringle
2-protease (F-G-K1-K2-P). Many potential binding sites are avail-
able on tPA for cells and fibrin, but the most important sites for
fibrinolysis appear to be in the F and K2 domains,14-16 and refined
mutagenetic analysis indicates that K2 is less involved in fibrin
binding than expected.17 However, studies performed to date do not
take into consideration the specific roles of tPA domains in fibrin of
variable structure as well as their distinct function in the rearrang-
ing fibrin architecture in the course of lysis.
Hence, there is a need to clarify the influence of fibrin structure
on rates of fibrinolysis. We have established a number of tools to
facilitate such investigations by examining the effects of fibrin both
Submitted June 10, 2010; accepted October 6, 2010. Prepublished online as
Blood First Edition paper, October 21, 2010; DOI 10.1182/blood-2010-
06-290338.
The online version of this article contains a data supplement.
The publication costs of this article were defrayed in part by page charge
payment. Therefore, and solely to indicate this fact, this article is hereby
marked ‘‘advertisement’’ in accordance with 18 USC section 1734.
© 2011 by The American Society of Hematology
661BLOOD, 13 JANUARY 2011  VOLUME 117, NUMBER 2
For personal use only. at SEMMELWEIS UNIV OF MEDICINE on January 13, 2011. www.bloodjournal.orgFrom 
as a template and enzyme substrate. Precise kinetic assays and
microscopic studies applied in conjunction with engineered vari-
ants of tPA, including fluorescent chimeras, have highlighted the
interplay between tPA binding, changes in clot structure during
lysis, and regulation of fibrinolysis. These findings have important
implications in situations of hypofibrinolysis and failed thrombo-
lytic therapy.9,18
Methods
Kinetic methods
Plasminogen activation assays were performed as previously described19 in
microtiter plates using preformed clots of 9.1M fibrinogen (human,
plasminogen depleted from Calbiochem), incorporating 166nM plasmino-
gen (Chromogenix), which were overlaid with a solution containing
plasminogen activator and plasmin chromogenic substrate (S-2251, Val-Leu-
Lys-p-nitroaniline, Chromogenix). The WHO 2nd IS for thrombin (01/580,
NIBSC)20 was used as a pure form of -thrombin to clot fibrinogen, where
1 IU/mL is equivalent to approximately 10.7nM by active site titration.21
Fibrin formed using different thrombin concentrations is referred to for
clarity using a subscript notation, fibrinx, where x denotes approximate
concentration in nanomolar units. Thus, for example, fibrin100 denotes fibrin
clotted by thrombin at approximately 10 IU/mL, which has been rounded to
100nM. Plasmin generated at the clot interface was monitored by following
absorbance at 405 nm (Thermomax plate reader, Molecular Devices), and
rates of plasminogen activation were calculated as previously described.19
To investigate both plasminogen activation and fibrin lysis by tPA, under
the same reaction conditions, parallel plates containing identical clots were
prepared and to one plate activator and S-2251 were added to initiate
plasminogen activation and measurement, whereas plasminogen activator
in buffer only (no S-2251) was added to the second plate. In both cases,
readings were taken at dual wavelengths of 405 and 650 nm, and kinetic
data were prepared by subtracting 650 nm readings from 405 nm readings
to remove interference from any bubbles developing in the clots. In the
plate with S-2251, data were analyzed to calculate plasminogen activation
rates as absorbance change per second squared over the initial period of
reaction ( 0.1 absorbance change, before depletion of substrates22). In the
second plate without S-2251, data from changes in clot turbidity were used
to estimate rates of fibrinolysis, expressed as time to a percentage lysis,
where 100% lysis is taken as initial absorbance minus final absorbance of
the fibrin clots in the wells. Mineral oil was added to all reactions to prevent
evaporation. Large sets of kinetic data from 96-well plates monitored over
8 hours with readings at 1-minute intervals were manipulated using Excel
spreadsheets and routines written in Matlab (The Mathworks).
To measure fibrinolysis as collapse of clots, independent of turbidity
measurements, the “bubble release” method followed was as described by
Sands et al.23 Briefly, 0.2 mL of a mixture of a series of dilutions of
plasminogen activator and thrombin solution was dispensed into tubes to
which 1.0 mL of a mixture of fibrinogen and plasminogen was added. The
final concentrations in the reaction mixtures were 3.8M fibrinogen,
200nM plasminogen, thrombin 100 or 10nM, and tPA 2.4 to 0.3nM in
doubling dilutions. Activity of recombinant tPA and variants is traceable to
the WHO 3rd International Standard for tPA (98/714, NIBSC) and
10 000 IU is equivalent to 20 g or 0.31 nmol. Clots form rapidly in this
system, and bubbles can be seen to develop within the clot. The time taken
for clot lysis was recorded as the time the bubbles are suddenly released and
rise to the surface.
Generation and purification of tPA variants
Three tPA domain variants were expressed: normal tPA (domains Finger,
Growth factor, Kringle 1, Kringle 2, and Protease, F-G-K1-K2-P), K1K1-
tPA (F-G-K1-K1-P), and delF -tPA (G-K1-K2-P). To achieve this, deriva-
tives of pFastBac-tPA24 were generated by site-directed mutagenesis via
QuikChange (Stratagene) according to the manufacturer’s protocol. All
constructs were checked by sequence analysis. A deletion mutant lacking
the finger domain (V4-V46) was generated and designated pFastBac-F. A
variant in which the kringle 2 domain was replaced by a second copy of the
kringle 1 domain, designated pFastBac-tPA:k1k1, was generated in 3 steps:
the first step was to delete k2 (C180-C261) to generate pFastBac-tPA:k2.
In the second step, a silent SgrA1 restriction site was introduced upstream
of the k2 deletion site D179:S262, and a silent AflII restriction site was
introduced downstream of D179:S262. In the third step, k1 was amplified
by PCR using primers, including SgrA1 and AflII restriction sites, and the
product was ligated to pFastBac-tPA:k2 to create pFastBac-tPA:k1k1.
pFastBac-tPA (and derivatives) were modified to express C-terminal
fusions of tPA with enhanced green fluorescent protein as follows: the
“stop” codon of tPA was modified to an XbaI restriction site by site-directed
mutagenesis. The XbaI fragment of plasmid enhanced green fluorescent
protein (GFP; Clontech) that includes the coding sequence for enhanced
GFP was ligated to the XbaI site, introduced at the 3 end of tPA, to create an
in-frame fusion, including a 10-amino acid linker. Details of primers are
available on request.
tPA and derivatives, expressed as previously described,24 were purified
directly from the culture media using an Erythrina inhibitor (Landing
Biotech)–Sepharose column. Proteins were visualized by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis for size and purity and quanti-
tated using Coomassie Plus Protein Assay Reagent (Pierce Chemical) with a
standard curve of tPA quantified by amino acid analysis (Alta Bioscience).
SEM imaging of fibrin
Fibrinogen (human, plasminogen-depleted from Calbiochem), 6M in
25mM Na-phosphate pH 7.4 buffer containing 75mM NaCl and 500nM
plasminogen, was clotted for 1 hour at 37°C with 5 or 100nM thrombin in
Eppendorf tubes (pretreated with 25% [vol/vol] Triton X-100 solution for
1 hour and thoroughly washed with water). Thereafter the whole clot
(50 L) was transferred into 500 L 40nM tPA. The digestion was stopped
at various times with ice-cold 100mM Na-cacodylate, pH 7.2, buffer for
5 minutes followed by fixation in 1% (vol/vol) glutaraldehyde for 30 minutes.
The fixed samples were dehydrated in a series of ethanol dilutions
(20%-96% vol/vol), 1:1 mixture of 96% (vol/vol) ethanol/acetone, and pure
acetone followed by critical point drying with CO2 in E3000 Critical Point
Drying Apparatus (Quorum Technologies). The specimens were mounted
on adhesive carbon discs, sputter coated with gold in SC7620 Sputter
Coater (Quorum Technologies), and images were taken with scanning
electron microscope EVO40 (Carl Zeiss) and the manufacturer’s software.
Confocal microscopic imaging in the course of fibrinolysis
Fibrin clots were prepared from 6M fibrinogen containing 90nM Alexa-
Fluor 546-conjugated fibrinogen (Invitrogen) and 500nM plasminogen,
clotted with thrombin for 30 minutes in 0.5-mm-high chambers constructed
from glass slides. Thereafter 40nM tPA-GFP was added to the edge of the
clot, and the fluorescence (excitation wavelength 488 nm, emission wave-
length 525 nm for tPA-GFP detection, and excitation wavelength 543 nm,
emission wavelength 575 nm for Alexa-546-fibrinogen detection) was
monitored with Confocal Laser Scanning System LSM510 (Carl Zeiss)
taking sequential images of the fluid-fibrin interface at a distance of
approximately 50 m from the glass surface with identical exposures and
laser intensities using Plan-Neofluar 20/0.5 objective. When indicated in
a figure, the color channels of the original images were separated or
overlaid using the Image Processing Toolbox of Metlab (The Mathworks).
Results
Enzyme kinetic studies
The kinetic methods developed here, using preformed clots where
plasminogen activator is added externally, permit parallel monitor-
ing of plasminogen activation and fibrin degradation under the
same reaction conditions. Plasminogen activation is followed by
absorbance at 405 nm (hydrolysis of chromogenic substrate), and
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fibrin lysis is monitored in a parallel plate by following decreasing
turbidity in identical clots. Representative data from such an
analysis are shown in Figure 1 for coarse fiber, open pore fibrin,
and thin fiber, fine mesh fibrin, formed using 5nM thrombin
(fibrin5) and 100nM thrombin (fibrin100), respectively. Morphomet-
ric analysis of fibrin structure from scanning electron microscope
(SEM) images is presented in supplemental data (available on the
Blood Web site; see the Supplemental Materials link at the top of
the online article). For the 3 tPA variants shown, both plasminogen
activation and overall fibrinolysis rates were affected by the
different fibrins studied. Figure 1 shows that times for 50% and
100% lysis were shorter in fibrin100, but assessment of fibrinolysis
rates by absorbance was complicated by transient increases in
absorbance during lysis of fibrin5 (see inset), which may lead to
underestimation of the rate of fibrin degradation in fibrin5, espe-
cially at earlier times. Behavior of the domain variants was
significantly different in the coarse and fine fibrin, particularly the
delF-tPA, which demonstrated a marked lag in plasminogen
activation in fibrin5. Fibrin100, by contrast, appeared to provide an
efficient surface for all the tPA variants studied.
Experiments using the same techniques over a range of tPA
concentrations were performed, and results for plasminogen activa-
tion are presented in Figure 2. In this case, data from fibrin10 are
discussed to avoid the complications caused by transient increases
in absorbance seen during lysis of fibrin5. Figure 2 shows how the
potency of tPA was markedly affected by the nature of the fibrin,
but the effect diminished as tPA concentration increased. In this
representative example, the lowest tPA dose (0.15nM) had a more
than 2-fold higher potency as plasminogen activator in fibrin100
compared with fibrin10. By contrast, fibrinolysis rates in the same
clots (turbidity changes in the clot, not shown) were slower in
fibrin100 such that tPA potency was calculated to be 73.8%
(62.1%-87.1%) as active in fibrin100 compared with fibrin10. These
results highlight the resistance of fine fibrin as a substrate for
plasmin counter to its augmented function as a template for
plasminogen activation. Fibrin100 was also found to be more
resistant to fibrinolysis in the “bubble release” assay format, where
measurements do not depend on clot turbidity changes and tPA is
incorporated throughout the clot (data not shown). In this format,
there was also a small but consistent decrease in tPA potency in
fibrin100 such that tPA had 86.9% (83.1%-90.8%) potency com-
pared with fibrin10.
Microscopy studies
Having established these opposing effects of fibrin structure on
plasminogen activation and fibrinolysis, changes in fibrin during
lysis were investigated using microscopy. Figure 3 shows typical
examples of clots formed of fibrin100 and fibrin5, before and after
10 minutes of lysis, after the addition of tPA. There are clear
differences in fiber thickness and pore structure as seen in Figure
3A and B, but also significant differences in the progress of lysis
between the 2 types of fibrin (Figure 3C-D). Significantly, fibrin5
lysis is accompanied by the generation of discrete, dense fibrin
structures not seen in fibrin100. Although there are some method-
ologic differences in the approach used in Figure 3 to prepare clots
Figure 1. Fibrinolysis and plasminogen activation kinetics by tPA (circles),
K1K1-tPA (triangles), and delF-tPA (squares) in fibrin clots prepared using
different thrombin concentrations. Thrombin concentrations used to form the clots
were 5nM (A, fibrin5) and 100nM (B, fibrin100). Representative data using 0.075nM
tPA are shown for plasmin generation measured by hydrolysis of S-2251 at 405 nm
(positive absorbance change) and simultaneously for lysis of fibrin clots (negative
absorbance change, in the absence of S-2251). Large open symbols represent the
time points to 50% lysis of each clot; and the solid symbols show the time points for
100% lysis. Small symbols are included on plasminogen activation curves for
identification purposes. The 3 plasminogen activation curves for the tPA variants in
panel B are very close, indicating very similar activities. The arrows show the times
for 50% and 100% lysis for tPA. The inset is a magnified view focusing on the initial
rates of fibrinolysis in fibrin5.
Figure 2. Plasminogen activation rates over a range of tPA concentrations in
the presence of fibrin formed at high and low thrombin concentrations. Clots
were prepared using thrombin at 100nM fibrin100 (, solid line) or 10nM fibrin10
(E, dashed line) and subsequently tPA from 0.15 to 1.2nM overlaid in the presence of
S-2251. Initial rates were measured up to an absorbance change of 0.1. Data are
plotted as log dose tPA (nM added to the clot) versus log response (rate of change of
absorbance/s2  109).
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for SEM and the clots used in the kinetic experiments in Figure 1, it
may be proposed that these aggregates are responsible for the
transient increase in absorbance noted for fibrin5 lysis, which peak
during the first 30 minutes or so after tPA addition.
Further work on the time course of lysis of fibrin clots was
performed using confocal microscopy in conjunction with
tPA-GFP added to clots formed of fibrin100 and fibrin5 and the
progress of lysis followed over time, as shown in Figure
4. These data also indicate that the front of the fibrin clot moves
faster in fibrin5 than in fibrin100, in general agreement with the
trends discussed above in relation to Figures 1 and 2. There are
also morphologic differences that develop in the 2 fibrins as
indicated by the pattern of fluorescence, which reflects tPA
distribution. Specifically, it can be seen that a granular pattern
develops in the fibrin5 lysis series in contrast to the homoge-
neous fluorescence pattern that is maintained in the fibrin100
series. Time-lapse animations of the lysis front movement in fibrin100
and fibrin5 are also available in supplemental Videos 1 and 2.
It may be proposed that the granules seen in Figure 4A are the
same protein aggregates seen in Figure 3C as their size is of the
same order: SEM aggregates mean diameter  5.74 m
(SD  2.01 m, n  25); and fluorescent grains mean
diameter  5.04 m (SD  2.23 m, n  20). Further evidence of
the binding of tPA to aggregates formed in fibrin5 is provided in
Figure 5, using orange fluorescent fibrinogen converted to fluores-
cent fibrin100 and fibrin5. Fluorescent aggregates in orange fibrin5
are coincident with the green fluorescence of tPA-GFP (Figure 5C),
whereas the distribution of red and green fluorescence is more
homogeneous in the lower panels showing fibrin100.
The nature of the fluorescent grains formed by tPA-GFP at the
fibrin5 interface was approached with known modifiers of the
tPA-fibrin interactions. Carboxypeptidase B, which eliminates new
C-terminal lysine residues exposed in the course of fibrin digestion
by plasmin, slows down the migration of the lytic front in the
experimental setup described in Figure 4, if it is added to fibrin at
the time of clotting at 8 U/mL (data not shown). However, it does
Figure 3. SEM images of fibrin clots formed using
high and low thrombin concentrations before and
during lysis using tPA. (A-B) The structure of fibrin5 and
fibrin100 formed at 5 and 100nM thrombin, respectively.
Insets are areas from panels A and B at higher magnifica-
tion to show more detail of the fibrin fiber structure
present in each clot. (C-D) The same kind of fibrin but
after 10 minutes of lysis after the addition of tPA to the
surface of the clot. (C) Characteristic fibrin aggregate
structures in fibrin5 that are not formed in fibrin100.
Figure 4. Confocal microscopy showing a time course
of lysis of fibrin clots formed using high and low
thrombin concentrations in the presence of tPA-GFP.
(A) The pattern of tPA binding and fibrin lysis as the fibrin
front recedes for fibrin formed using 5nM thrombin (fi-
brin5). (B) The same time course for fibrin formed at
100nM thrombin (fibrin100). Images were taken at the
indicated time after the addition of tPA-GFP, and the
green channel components of the sequential frames were
overlaid in a single image for presentation purposes. A
characteristic granular pattern of fluorescence can be
seen at the lysis front in fibrin5, whereas in fibrin100 the
tPA-GFP is distributed more homogeneously.
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not eliminate the fluorescent aggregates, only delays their forma-
tion on the surface of fibrin5 (supplemental Figure 2). 6-aminohex-
anoate, which interferes both with tPA and plasmin(ogen) binding
to fibrin, dissipates the granular pattern of tPA-GFP related
fluorescence only at high concentrations  0.1mM, where binding
and inhibition of plasmin can become significant (supplemental
Figure 2). Thus, the exposure of C-terminal lysines does not seem
to be a crucial step for the formation of fibrin aggregates. Attention
was therefore focused on tPA finger domain binding to fibrin
aggregates and the known interaction with cross -sheet struc-
tures.25 Thioflavin T, which binds to cross -sheets,26 was used to
probe the presence of cross -sheets in fibrin aggregates formed
during lysis. Colocalization of tPA-GFP to sites that also bind
thioflavin T was observed (supplemental Figure 3). To further
investigate the significance of tPA finger domain in interactions
with fibrin aggregates, a finger-deleted variant of tPA with fused
GFP was constructed and used in the experimental setup of Figure
4. In agreement with the observations of a lag phase seen in Figure
1 using delF-tPA, delF-tPA-GFP took longer to accumulate at the
fibrin-solution interface of clots formed of fibrin5. However, a
strong fluorescence signal at the boundary was eventually seen, and
lysis progressed with the formation of some heterogeneous fluores-
cent aggregates. These were not as strong or long lived as with
tPA-GFP, and the lytic front was observed to dissipate after 15
minutes, leaving a wider distribution of fluorescent tPA signal than
seen with tPA-GFP. Subsequently, the fluorescence of delF-tPA-
GFP was seen to travel ahead of the clot edge, leaving behind
structures that appeared as a “starburst” pattern. delF-tPA-GFP is a
marker for C-terminal lysines, which appear to have a wide
distribution around the lysis front. By contrast, tPA-GFP was very
focalized on aggregates in fibrin5, suggesting that finger domain-
fibrin aggregate binding is particularly important. Selected snap-
shots of the progress of clot lysis in fibrin5 with delF-tPA-GFP are
shown in Figure 6 and presented as a time lapse movie in
supplemental Video 3. Once again, the situation with fibrin100 was
notable for a lack of distinct larger fluorescent aggregates and a
more homogeneous zone of lysis. However, there was also
evidence of delF-tPA-GFP moving ahead of the fibrin/buffer
interface, which forms the lytic front when full-length tPA-GFP is
the activator.
Discussion
Fibrinolysis and clot structure
Fibrinolysis may be considered as a 2-step process,27 and the work
presented here shows the value of approaching plasminogen
activation and the whole process of fibrinolysis as distinct yet
overlapping processes. We observe that the behavior of fibrin as a
template for the stimulation of plasminogen activation is indepen-
dent of the effectiveness of fibrin as a substrate for plasmin. A key
feature in understanding the regulation of fibrinolysis highlighted
in the current study is the formation of fibrin aggregates, identified
in the microscopic images of Figures 3 and 5 and clearly able to
bind tPA as shown in Figures 4 and 5. The relationship between
fibrin structure and rate of fibrinolysis is not simple and is
complicated by several factors. These include (1) the lack of
correlation of effectiveness of fibrin as a stimulator for plasmino-
gen activation and a substrate for plasmin, (2) the different dose
dependencies of tPA concentration and rate seen in Figure 2, and
(3) the presence of fibrin aggregates, which cause a heterogeneous
distribution of tPA and also interfere with absorbance measure-
ments. These confounding factors may account for conflicting
results in some studies discussed in the Introduction,1 which could
arise from subtle differences in experimental arrangements.
Although it is often observed that coarse clots formed of thick
fibers lyse more rapidly than clots of thin fibers, at the molecular
level of fibrin fibers it has been noted that individual thin fibrin
fibers may be dissolved more rapidly than thick fibers.4,5 A model
has been proposed whereby plasmin cuts fibers by focused lateral
transection (“crawling”) rather than more general surface erosion,28
and larger fibers lead to more efficient fibrinolysis by assisting the
“crawling” of plasmin.29 A somewhat different interpretation points
to reduced dimensionality of enzyme action and more focalized
attack of plasmin in coarse fibers.5 In their detailed analysis and
modeling of fibrin degradation, Walker and Neshiem30 also con-
cluded that fibrin lysis by plasmin occurs through limited discrete
cleavage that is nonrandom. Furthermore, they observed that large
fibrin degradation product fragments released from clots could
reassociate, and the affinity of the fibrin degradation products for
Figure 5. Colocalization of tPA-GFP with fibrin protein
aggregates. Orange-labeled fibrinogen was clotted with throm-
bin at 5nM (A-C, fibrin5) or 100nM (D-F, fibrin100) and fibrinolysis
initiated with the addition of tPA-GFP. After 35 minutes of lysis,
micrographs were taken of green fluorescence (A,D) and red
fluorescence (B,E). (C,F) Overlays of the corresponding single
fluorescent micrographs for each fibrin type. Fibrin5 shows the
granular pattern of fibrin aggregates noted previously, which
can be seen to bind tPA. (C) Overlay also shows a number of
green particles of precipitated tPA-GFP. Fibrin100 displays a
narrow zone of bound tPA and few fibrin aggregates.
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the clot was proportional to their size. It is possible that the large
protein structures seen during early stages of fibrinolysis in fibrin5
(Figure 3C) are these aggregates of fibrin degradation products that
bind to the clot in the zone of lysis and are responsible for the
transient increases in absorbance noted above (Figure 1A inset).
Fibrinolysis in fine structured fibrin100 clots would thus result in
smaller fragments, with weaker affinity and less tendency for
rebinding to the clot. The concentration of tPA around fibrin
aggregates would lead to focal points of activation of plasminogen,
and this may be a mechanism of localized fibrinolysis that does not
rely entirely on the behavior of plasmin.
tPA domain-fibrin binding
Results obtained using tPA variants have allowed us to dissect out
the role of tPA domains at different stages of fibrinolysis. Micro-
scopic and kinetic studies using tPA variants and GFP chimeras that
interact via F and K2 domains together, and F or K2 alone, allow us
to follow the initial interactions and subsequent pattern of tPA-
fibrin binding to build up a more complete picture of the process of
fibrinolysis. A number of previous studies have been published that
use fluorescein isothiocyanate plasminogen or fibrinogen31 as a
marker of fibrinolysis or colloid labeled fibrinogen or FITC-tPA.4
The current confocal microscopic studies focused on tPA behavior
using tPA-GFP, which is specifically labeled at the C-terminus to
avoid interference with binding domains yet retains high enzymatic
activity (not shown). The process followed in Figure 4 highlights
the marked difference in tPA-binding behavior and lysis of fibrin100
and fibrin5, where a homogeneous distribution or distinct “hot
spots” of bound tPA are seen, respectively. Similar fluorescent
agglomerates have also been seen when FITC-plasminogen has
been used as the marker for active fibrinolysis during studies of
fibrin clots formed in plasma, whose fibrin structure corresponds to
the coarse morphology found in clots made from purified fibrino-
gen at low thrombin concentrations.31,32 Thus, fibrin aggregates
have previously been shown to bind plasminogen, and we have
extended these observations using time-lapse microscopy and
kinetic studies to highlight the role of the finger domain in
localizing tPA to fibrin aggregates formed in coarse fibrin. Where
fine fibrin is the stimulator of tPA, the domain structure has less
influence and plasminogen activation is more efficient with all
variants examined than in coarse fibrin. The limiting factor in fine
fibrin fibrinolysis is plasmin digestion of fibrin.
Questions surrounding the precise binding sites for tPA and
plasminogen in fibrin have been around for many years, and several
specific sites that are cryptic in fibrinogen but become exposed in
fibrin have been proposed.7,33 However, the search has not been
entirely successful, and no consensus has been achieved on binding
sites and strength to fully explain tPA stimulation by fibrin. Caution
has been advised over this “reductionist” approach,34 and more
evidence is required if specific binding sites are to be definitively
established. From the current work, a model of fibrinolysis
characterized by 3 distinct modes of binding can be proposed.
Initial F-dependent binding sites of special significance in coarse
fibrin appear to be important. Subsequently, K2-dependent binding
to new C-terminal lysine sites will further enhance binding in a
well-characterized way.35,36 Data presented above (supplemental
Figure 3) that colocalize tPA binding and thioflavin T binding
supports the idea that the third mode of tPA binding is to a cross-
structural motif.25 tPA is known to be a promiscuous binding
molecule, and previous studies have identified tPA binding to
aggregates with a variety of proteins, including biotherapeutics and
amyloid plaques.37,38 We propose that the aggregates seen in Figure
Figure 6. Progress of fibrinolysis in fibrin5 formed
using 5nM thrombin with delF-tPA-GFP. The 4 panels
are snapshots of the distribution of delF-tPA-GFP during
fibrinolysis at the times indicated in the upper corner.
Initial binding and concentration of the delF-tPA-GFP to
the surface of the clot were slow, but after 10 minutes a
narrow zone of concentrated activator formed. Subse-
quently, some tPA diffused ahead of the fibrin-buffer
interface and was associated with some fibrin aggre-
gates; a proportion of delF-tPA-GFP also remained
close to the fibrin-buffer interface appearing as a “star-
burst” pattern.
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3C strongly bind tPA, and the finger domain is important for this
interaction. This mode of binding is necessarily important in
regulating the pattern of fibrinolysis in coarse fibrin. In the absence
of the finger domain, tPA is more widely distributed within coarse
fibrin and tPA K2 accumulation is a marker for the presence of
C-terminal lysines. The recently described thermodynamically
unstable -hairpins in the C-domains of fibrinogen39 may be
involved in the cross- structures of the agglomerates. The
C-domains are sensitive sites of plasmin action40 and, after early
digestion of this region, swapping of these -hairpins may stabilize
focally and transiently the partially degraded fibrin oligomers.
The in vitro studies presented here, including purified compo-
nents, may be questioned as nonphysiologic. However, a number of
reports suggest that fibrin(ogen) structure in vivo is very important
in regulating rates of fibrinolysis. Inevitably, fibrin and clot
structure/function relationships are more complicated in vivo than
suggested here as clots will include numerous proteins and cells
and other constituents, which can affect structure and hence lysis
rates.27 Recent work has also identified polyphosphate released
from platelets41,42 and red blood cells43 as important regulators of
fibrin fiber thickness, clot structure, and mechanical properties.
Further work is required to identify all the factors that regulate clot
structure, fibrin binding, plasminogen activation, and fibrin lysis.
However, Finger-dependent focalization on cross- structures in
coarse fibrin agglomerates generated primarily at the fibrin surface
during fibrinolysis may represent a previously underappreciated,
distinct mechanism of tPA binding that has important implications
for the regulation of fibrinolysis.
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